通过拉巴胺素诱导和促进Hspb1的扩散活动在一个细胞中
Takayuki Kitano1,2, Keiko Nishikawa1,2, Tetsuya Takagaki2
1Department of Molecular Pathogenesis, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
Experimental and therapeutic medicine
|June 5, 2023
概括
结核硬化综合体 (TSC) 治疗拉巴素增加了热冲击蛋白B1 (Hspb1) 的表达和酸化. Hspb1促进瘤细胞增殖,这表明它是TSC的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 结核性硬化综合体 (TSC) 是一种由TSC1或TSC2瘤抑制基因突变引起的遗传性疾病.
- 拉巴胺在TSC治疗中表现有前途,但通常会导致瘤在停止治疗后再次生长.
- 需要新的治疗点来克服TSC的残留瘤.
研究的目的:
- 研究Tsc2缺陷瘤细胞中对拉巴胺素敏感的信号通路.
- 专注于与热冲击蛋白相关的途径,以确定TSC的新治疗点.
主要方法:
- 分析了Rapamycin对热冲击蛋白家族B (小) 成员1 (Hspb1) 表达和酸化在Tsc2-缺乏细胞中的影响.
- 利用Hspb1的淘汰和过度表达来评估其在细胞增殖中的作用.
主要成果:
- 拉帕米辛治疗增加了Hspb1的表达和酸化.
- 在没有拉巴胺的情况下,Hspb1敲击抑制了细胞增殖.
- Hspb1过度表达增强了细胞增殖,有或没有拉巴胺素.
结论:
- Hspb1在TSC瘤细胞增殖中发挥着重要作用.
- 与hspb1相关的途径代表了结核性硬化综合体的潜在治疗点.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
TGF - β Signaling Pathway
7.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K


